Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized trial of cisplatin, paclitaxel, gemcitabine with or without bevacizumab in cancer of unknown primary
2007-000663-18Phase 2Terminated
- Sponsor
- Rigshospitalet
- Start
- Feb 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of bevacizumab in cancer of unknown primary (CUP) (2 arms), sponsored by Rigshospitalet. Primary endpoints: Response rate and Toxicity. Started Feb 2007; status: terminated.
02
Drugs
bevacizumab
03
Conditions
cancer of unknown primary (CUP)
Beyond the preview
Go deeper on 2007-000663-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-000663-18.